JP Morgan Chase’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

JP Morgan Chase’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-75,000	Closed	-$1.35M	–	6030
2020 Q2	$1.35M	Hold	75,000	–	–	﹤0.01%	3340
2020 Q1	$535K	Sell	75,000 -133,500	-64%	-$1.67M	﹤0.01%	3784
2019 Q4	$4.98M	Sell	208,500 -1,500	-0.7%	-$41.4K	﹤0.01%	2677
2019 Q3	$5.63M	Sell	210,000 -105,000	-33%	-$2.95M	﹤0.01%	2606
2019 Q2	$8.41M	Buy	315,000 +30,000	+11%	+$941K	﹤0.01%	2237
2019 Q1	$9.89M	Buy	+285,000	New	+$8.22M	﹤0.01%	2065
2018 Q4	–	Sell	-82,100	Closed	-$2.19M	–	6052
2018 Q3	$2.19M	Buy	+82,100	New	+$2.68M	﹤0.01%	3403

JP Morgan Chase's PTLA Position: Q3 2020 in Review

JP Morgan Chase sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q3 2020, closing a stake of 1,494,183 shares — an estimated $26.9M sold.

JP Morgan Chase first reported a position in PTLA in Q4 2013 and held it in 27 quarters. The position peaked at $42.4M in Q1 2019. 0 funds tracked by Wall St. Rank hold PTLA as of Q3 2020.

JP Morgan Chase reported no remaining Portola Pharmaceuticals, Inc. position as of Q3 2020 after selling out during the quarter.
JP Morgan Chase sold 1,494,183 Portola Pharmaceuticals, Inc. shares in Q3 2020, an estimated $26.9M.
JP Morgan Chase first reported a position in Portola Pharmaceuticals, Inc. in Q4 2013 and held it in 27 quarters.
JP Morgan Chase's Portola Pharmaceuticals, Inc. position peaked at $42.4M in Q1 2019.
0 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q3 2020.

Based on JP Morgan Chase's 13F filing for Q3 2020, filed 12 Nov 2020.